cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations

2019 PTC WMS Abstract – Steroid Use and DMD

2019 PTC WMS Abstract – Steroid Use and DMD

DEFLAZACORT OR PREDNISONE TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY (DMD): REAL-WORLD OUTCOMES AT CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER (CCHMC)

View the Full PDF

03
Apr 2019
Abstracts

Read the latest

  • Prognostic factors for loss of ability to rise from supine in DMD
  • Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
  • cTAP Study Shows Real-World, Natural History Data Comparable to Placebo Data from Clinical Trials in Duchenne Muscular Dystrophy
  • A prognostic model for 1 year change in 4SC
  • Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-duchenne.org

© 2021 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations